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Abbreviations 
ABPA Allergic bronchopulmonary aspergillosis 
AML Acute myeloid leukaemia 
CF Cystic fibrosis 
COPD Chronic obstructive pulmonary disease 
CNS Central nervous system 
CPA Chronic pulmonary aspergillosis 
cyp51  Cytochrome P450 14-α sterol demethylase gene (gene coding for a demethylase enzyme in 
the ergosterol biosynthesis pathway)  
DMI Demethylation inhibitors 
EBMT European Group for Blood and Marrow Transplantation 
EFSA European Food Safety Authority (EFSA) 
EORTC European Organisation for Research and Treatment of Cancer 
EUCAST European Committee on Antimicrobial Susceptibility Testing 
FRAC Fungicide Resistance Action Committee 
GINA Global Initiative for Asthma 
HSCT Haematopoietic stem cell transplant 
IA Invasive aspergillosis 
ICU Intensive care unit 
MIC Minimal inhibitory concentration 
MSG US Mycoses Study Group 
PCR Polymerase chain reaction 
SAFS Severe asthma with fungal sensitisation 
TR34/L98H  Resistance mechanism based on a 34-base pair tandem repeat in the gene promoter combined 
with a point mutation in the cyp51A gene at codon 98 leading to an amino acid change  
TB Tuberculosis 
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Executive summary 
In recent years, triazole resistance in human Aspergillus diseases appears to have been increasing in several 
European countries. However, current data on the prevalence of resistance are based on a small number of studies 
which are only available from a few European countries. If present, triazole resistance can severely limit treatment 
options since alternatives, which are only available in intravenous form, have been shown to be associated with 
more side effects and poorer outcomes. Triazole resistance in Aspergillus spp. can evolve during therapy. Several 
point mutations, particularly in the cyp51A gene, have been associated with the development of resistance. 
Increasingly however, resistant isolates are also being detected in azole-naive patients. These isolates tend to have 
a particular genetic alteration consisting of a 34-base pair tandem repeat in the promoter coupled with a point 
mutation in the cyp51A target gene. This leads to an amino-acid substitution at codon 98 (TR34/L98H) causing 
multi-azole resistance. In patients whose Aspergillus isolates have developed resistance during azole therapy wild-
type isolates, closely related genetically to the resistant isolates, have regularly been recovered from samples taken 
before the start of therapy or during an earlier phase. To date however, no isogenic isolate with a wild-type 
phenotype has been recovered from patients infected with an Aspergillus strain carrying the TR34/L98H genetic 
alteration. This suggests a possible environmental origin of the resistant fungus. This particular resistance 
mechanism has been observed most frequently in clinical isolates in the Netherlands where it has also been found 
in the environment. Moreover, the resistance mechanism has been demonstrated in clinical isolates in eight other 
European countries.  
Azole fungicides are widely used for crop protection and material preservation in Europe. They protect crops from 
disease, ensure yields and prevent fungal contamination of produce. It has been proposed that triazole resistance 
has evolved in the environment and could be driven by the selective pressure of azole fungicides. Although 
evidence supporting this hypothesis is growing, the link between the environmental use of azole fungicides and the 
development of triazole resistance in Aspergillus spp. is not yet proven.  
Triazole therapy has become the established treatment for invasive aspergillosis and is widely used in the 
treatment of allergic aspergillosis and chronic pulmonary aspergillosis. Antifungal therapy for invasive pulmonary 
aspergillosis is usually prescribed for a minimum of 6–12 weeks, but often may need to be continued for months 
depending on the period of immunosuppression. Treatment of allergic aspergillosis and chronic pulmonary 
aspergillosis may need to continue for years or even throughout a patient’s lifetime. We estimated the burden of 
allergic, chronic and invasive aspergillosis using population statistics and published literature. Of the 733 million 
inhabitants in the European region1 [1], at any one time 2 100 000 patients may be suffering from allergic 
aspergillosis and 240 000 from chronic aspergillosis, that would be an indication for antifungal therapy. For invasive 
aspergillosis, we have estimated an annual incidence of 63 250 cases, complicating multiple underlying conditions 
including leukaemia, transplantation, chronic obstructive pulmonary disease (COPD) and medical intensive care. 
The inability to treat these patients with triazoles due to multi-azole resistance would have significant impact on 
patient management and associated health costs.  
Early and thorough investigation of this emerging public health problem is warranted in order to avoid the 
development and spread of resistance. This report examines current evidence for the environmental origin of 
resistance in Aspergillus spp. and makes recommendations for further steps to assess the risks and consequences 
of the environmental usage of azole derivatives. Improved surveillance of clinical isolates, including antifungal 
susceptibility testing, is the key to a better understanding of the magnitude of this emerging problem. Furthermore, 
the diagnosis of Aspergillus diseases needs to be improved and molecular methods allowing detection of resistance 
in culture-negative specimens must be further developed and implemented in laboratory practice. Finally, further 
environmental and laboratory studies are needed to confirm the environmental hypothesis. 
Source and date of request 
Request from the Netherlands, during the 24th Advisory Forum at ECDC, Stockholm, 8–9 December 2010, to 
organise expert meetings to support further investigation into the environmental origin of triazole resistance in 
Aspergillus diseases.  
  
 
                                                                    
1 For this report the European region was defined as the 27 EU Member States plus Albania, Andorra, Belarus, Bosnia and 
Herzegovina, Croatia, the Faeroe Islands, Iceland, Liechtenstein, the former Yugoslav Republic of Macedonia, the Republic of 
Moldova, Montenegro, Norway, the Russian Federation, Serbia, Switzerland and Ukraine. 
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Public health issue 
Potential implications for human health through the environmental application of azole fungicides. 
The objectives of this risk assessment were: 
• To review current evidence on the environmental origin of triazole resistance in Aspergillus spp.; 
• To assess the size and relevance of the problem for human health; 
• To identify priorities for further investigation of this public health issue; 
• To raise awareness and provide relevant authorities and decision-makers with options for action to control 
the emerging problem of azole-resistance in Aspergillus diseases. 
Expert panel 
Two meetings with experts from Europe and the USA were held: on 26 April 2011 in Amsterdam, the Netherlands 
and on 16 January 2012 at ECDC in Stockholm, Sweden. The participants are listed below. 
Surname First Name Institution Country 
Adriaenssens Niels University of Antwerp Belgium 
Arendrup Maiken C. Statens Serum Institut Denmark 
Bowyer Paul University of Manchester United Kingdom 
Chiller Tom Centers for Disease Control and Prevention USA 
Cuenca-Estrella Manuel Spanish National Centre for Microbiology. Instituto de Salud Carlos III Spain 
Denning David W. University Hospital of South Manchester United Kingdom 
Donnelly J. Peter Radboud University Nijmegen Medical Centre Netherlands 
Fraaije Bart Rothamsted Research United Kingdom 
Kema Gert H.J. Wageningen University Netherlands 
Kortbeek  Laetitia M. National Institute for Public Health and the Environment Netherlands 
Melchers Willem J.G. Radboud University Nijmegen Medical Centre Netherlands 
Ullmann Andrew University Hospital of Würzburg Germany 
van de Sande-Bruinsma Nienke National Institute for Public Health and the Environment Netherlands 
Verweij Paul E. Radboud University Nijmegen Medical Centre Netherlands 
Kleinkauf Niels European Centre for Disease Prevention and Control EU 
Monnet Dominique European Centre for Disease Prevention and Control EU 
External consultation 
The final report was submitted to the European Food Safety Authority (EFSA) and its comments were taken into 
account. 
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Background 
The term aspergillosis refers to a group of diseases which can result from Aspergillus infection, and host factors 
largely determine the type of clinical entity. It includes allergic bronchopulmonary aspergillosis (ABPA), chronic 
pulmonary aspergillosis (CPA), aspergilloma and the most severe form, invasive aspergillosis (IA). Some asthma 
patients with very severe asthma may also be sensitised to fungi-like Aspergillus (SAFS). Aspergillus fumigatus is 
by far the most common species in human Aspergillus infections, constituting more than 80–90 % of the isolates in 
most series [2-4]. In recent years, Aspergillus spp. and aspergillosis have been a major focus of clinical mycology 
because the number of patients with this disease has risen dramatically and the disease is difficult to diagnose and 
treat. The number of Aspergillus infections has increased because more patients are at risk of being exposed to 
this opportunistic pathogen and it is difficult to prevent the diseases it causes. Patients with established IA have 
poor outcomes. Successful therapy depends not only on an early diagnosis, which is difficult to establish, but also 
on the reversal of underlying host immune defects and the timely and effective use of antifungal agents. New 
diagnostic approaches have been introduced and antifungal agents have been developed for the treatment of 
aspergillosis. Particularly the newer azoles have become the mainstay of therapy and are the recommended first-
line drugs in the treatment and prophylaxis of aspergillosis. Resistance in Aspergillus spp. has long been considered 
a rare event and has only been reported at low frequency, mainly in case reports. In recent years however, the 
situation has changed considerably. Several reports have been published and surveillance studies have been 
performed particularly in northern Europe, many of these indicating that there is an increase in the frequency of 
azole resistance in A. fumigatus. Studies from the United Kingdom and Spain have demonstrated an increase in the 
frequency of triazole resistance showing that the cyp51 mutations found were due primarily to pressure under 
azole therapy [5-8]. At the same time there has been an increase in multi-triazole-resistant A. fumigatus, 
particularly in the Netherlands [9-11]. Here, the resistant strains were isolated from both azole-exposed and azole-
naive patients, as well as from the environment. The majority of the resistant isolates carried a single resistance 
mechanism, based on a 34-base pair tandem repeat in the gene promoter combined with a point mutation in the 
cyp51A gene at codon 98 leading to an amino acid change (TR34/L98H), and it was concluded that they were 
derived from the environment and may have evolved under the selective pressure of fungicides used in agriculture. 
The genetic alteration encoding this particular resistance mechanism appears to be spreading and has to date been 
detected in environmental samples in the Netherlands, Denmark, Norway, Italy and the UK (personal 
communication, D. Denning) and in patient isolates from nine European countries, India and China (Table 1) [5, 9, 
12-19]. The emergence of multi-azole resistance in A. fumigatus may significantly impact on the therapeutic role of 
azoles in aspergillosis, as it would rule out the use of oral antifungals, leaving only the option of intravenous 
amphotericin B or echinocandins for life-threatening infections. The predictable consequence of resistance is 
increased morbidity, prolonged illness, a greater risk of complications, and higher mortality rates. 
Table 1. Overview of countries that have reported TR34/L98H in Aspergillus spp. isolates from 
clinical or environmental samples 
Country Clinical samples Environmental samples Reference 
TR34/L98H 
reported 
Yeara TR34/L98H 
reported 
Yeara  
Netherlands + 1998 + 
(cultivated soil, 
compost, seeds 
and leaves, air 
samples)  
2002 [9, 77] 
Norway - N/Ab + 
(fjord water) 
2001 [9] 
Spain + 2003 -c N/A [12, 78] 
United Kingdom + 2006 + 
(rural area) 
2011 [5], D. Denning, 
personal 
communication 
Denmark + 2007 + 
(soil samples) 
2009 [15, 78] 
China + 2008 - N/A [13] 
India + 2008 - N/A [16] 
Austria + 2009 -c N/A [71, 78] 
Belgium + 2009 - N/A [71] 
France + 2009 - N/A [71] 
Italy + 2009 + 2011 [18, 71] 
Germany + 2012 - N/A [19] 
a Year of first recovery. 
b N/A - not applicable. 
c Soil samples were investigated, but TR34/L98H was not found. 
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In April 2011, the European Centre for Disease Prevention and Control (ECDC) arranged a first meeting to discuss 
the increasing problem of azole resistance in A. fumigatus with a particular focus on the possible environmental 
origin of resistance to medical triazoles. Public health experts, clinicians, agrochemical researchers and mycology 
reference laboratories were represented. A second meeting was held in January 2012. The current report 
represents a summary of the findings and proposals from the expert meetings. 
Burden of aspergillosis in the European region 
In 2010, the population of the European region (defined for this report as being the 27 EU Member States, plus Albania, 
Andorra, Belarus, Bosnia and Herzegovina, Croatia, the Faeroe Islands, Iceland, Liechtenstein, the former Yugoslav 
Republic of Macedonia, the Republic of Moldova, Montenegro, Norway, the Russian Federation, Serbia, Switzerland and 
Ukraine) was estimated by Eurostat to be 733 million inhabitants [1]. The numbers of patients in Europe suffering from 
aspergillosis is difficult to ascertain as figures have been obtained in a patchwork fashion, based on estimates from 
individual centres or countries. In the absence of proper registration, the best way to estimate the prevalence of 
aspergillosis is to rely on the validated population statistics for Europe (Eurostat), and apply the published frequencies of 
ABPA, SAFS, CPA and IA. Allergic fungal rhinosinusitis has not been considered in this estimation as it has not been 
demonstrated to respond to antifungal therapy. Such estimates are only an approximation, especially as the frequency of 
disease in each locality will vary, depending on aspects such as the occurrence of underlying diseases, the demographics 
of the population and other poorly recognised factors such as genetic risk. In addition, medical awareness is not uniform 
and diagnostic capabilities vary substantially. The use of antifungal prophylaxis and case ascertainment itself varies 
greatly according to the hospital and community medical setting. 
Allergic aspergillosis 
The principal allergic Aspergillus diseases are ABPA, SAFS (which is usually driven by Aspergillus spp., but other fungi 
may contribute) and allergic Aspergillus rhinosinusitis. Fungal rhinosinusitis due to Aspergillus was not considered in 
the following estimates as it has not been demonstrated to be responsive to azole therapy. Using the Global Initiative 
for Asthma (GINA) report and other data [20, 21] the number of adult asthmatics in Europe has been estimated at 
35.5 million. The frequency of ABPA has only been estimated in referral populations and varies from 0.7 to 3.5% [22-
26]. We have used the median of these figures: 2.5%. These data suggest an ABPA burden of just under 900 000 
patients in Europe (Table 2). 
Table 2. Estimated burden of aspergillosis, European regiona, 2010 
Type of 
aspergillosis 
Predominant diagnoses 
of population at risk 
Population 
at risk 
(thousands) 
Percent 
aspergillosis in 
population at 
risk 
Annual burden of 
aspergillosis 
(thousands) 
Reference 
Allergic 
bronchopulmonary 
aspergillosis (ABPA) 
Asthma 35 500 2.5%  (0.7–3.5%) 
887 
(248–1242) [20, 87] 
Cystic fibrosis 29 15% 4.3 [34, 35] 
Severe asthma with 
fungal sensitisation 
(SAFS) 
Severe asthmab 3 550 33% (25–50%) 1 172 (888–1 775) [20, 87] 
Chronic pulmonary 
aspergillosis (CPA) 
Chronic obstructive 
pulmonary disease (COPD), 
tuberculosis, sarcoidosis, 
ABPA, pneumothorax 
>13 600 1–10% 240 [37, 38, 87] 
Invasive aspergillosis 
(IA) 
Myeloid haematological 
malignanciesc 44 7% 3.1 [39, 40] 
Lymphoid haematological 
malignanciesd N/A N/A 3.1 [42, 57] 
Haematopoietic stem cell 
transplant (HSCT) 11.4 7% 0.8 [43, 57] 
COPD hospital admissions 2 830 1.2% 34.0 [45] 
Solid organ transplantation 
(SOT) 30 0.75% 0.23 [47, 49] 
Medical intensive care 
admissions 1 100
e 2% 22 [52] 
 
a In 2010, the European region (defined for this report as the 27 EU Member States, plus Albania, 
Andorra, Belarus, Bosnia and Herzegovina, Croatia, Faeroe Islands, Iceland, Liechtenstein, the 
former Yugoslav Republic of Macedonia, Republic of Moldova, Montenegro, Norway, Russian 
Federation, Serbia, Switzerland and Ukraine) had a population of 733 million inhabitants. 
b Assumed to be 10% of asthmatic patients. 
c Acute myeloid leukaemia, myelodysplastic syndrome and myeloproliferative disorders d Acute lymphoid leukaemia, multiple myeloma, 
lymphoma and chronic lymphoid leukaemia. 
e Assumed 30% of all ICU beds are for patients with medical diagnoses [34]. N/A - not available. 
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Asthma can be graded by severity, but definitions differ [27]. Using a 10% rate, there are an estimated 3.6 million 
adult Europeans with severe asthma, who account for ~70% of all asthma healthcare expenditure [28]. Alternative 
estimates based on total population indicate that 1–3% of the total population (adults and children) have asthma 
that is difficult to control [29]. Sensitivity to fungi in this population varies due to different testing approaches and 
variable performance of skin prick testing reagents and serum fungal-specific IgE testing. However, the most 
conservative estimate, using a limited panel of tests, put the percentage with fungal sensitisation at 33% [30], 
with some much higher figures also published [31-33]. This 33% rate of fungal sensitisation equates to a 
population of adult SAFS patients in Europe of 1 172 000.  
Approximately 15% of patients with cystic fibrosis (CF) develop ABPA, and a larger number are colonised [34]. In 
the UK, CF occurs in 1 in 2 400 live births and a recent Europe-wide survey found 29 095 patients (2003–08) using 
multiple national registries [35]. This would imply ~4 300 patients with ABPA in the context of CF, although this 
probably overestimates the numbers as ABPA is less common in childhood.  
Chronic pulmonary aspergillosis 
Chronic pulmonary aspergillosis (CPA) is an uncommon complication of numerous pulmonary disorders including 
tuberculosis, sarcoidosis, ABPA, COPD, prior pneumothorax, cure of lung cancer, rheumatoid arthritis and 
occasionally occurring after IA [36]. Estimating the frequency involves ascertaining the frequency of the underlying 
diagnosis. We have attempted to do this for tuberculosis [37], ABPA [21] and sarcoidosis [38] which together 
account for about 50% of the total caseload seen in a national referral setting. The annual burden of tuberculosis-
related CPA cases in Europe is estimated at 36 000, for ABPA 76 000 and for sarcoidosis 8 400; a subtotal of 
120 400. Based on these assumptions, which accommodate a 15% annual mortality or surgical cure rate, 
approximately 240 000 adult Europeans have CPA at any one time (point prevalence). 
Invasive aspergillosis 
Invasive aspergillosis (IA) complicates haematological malignancy and its treatment relatively frequently. The 
commonest underlying disorder is acute myeloid leukaemia (AML), with an incidence of three per 100 000 
population [39]. There will therefore be around 22 000 AML cases in the European region each year. Add to this an 
annual incidence of three per 100 000 for other myeloid malignancies, including myelodysplastic syndrome and 
myeloproliferative disorders, which are associated with a high risk of IA, and the number of high-risk 
haematological patients doubles to 44 000. Seven out of 10 cases are adults and the rate of occurrence of invasive 
mould diseases is reported to be around 8%, with IA accounting for nine out of ten cases – i.e. overall rate of 
occurrence 7% [40]. There are therefore likely to be 3 100 cases of IA among patients treated for myeloid 
malignancies in the European region each year. Approximately equal numbers of IA cases occur in patients with 
acute lymphoblastic leukaemia, multiple myeloma, lymphoma and chronic leukaemia [41, 42]. Hence, there are 
likely to be 6 200 cases of IA among patients treated for haematological malignancies and lymphoma in the 
European region each year. 
In 2009, the European Group for Blood and Marrow Transplantation (EBMT) reported that there were 11 442 first-
time recipients of an allogeneic haematopoietic stem cell transplant [43]. These patients are at similar risk of 
developing IA in the months immediately following transplantation [20]. Therefore assuming a 7% rate of 
occurrence [44] there would be 800 cases of IA per year, bringing the total number among those treated for 
haematological malignancies to at least 7 000 cases per year. At least three times this number are treated for IA 
each year, some on multiple occasions during different risk periods, and improved non-culture-based diagnostic 
testing indicates that the 7% rate of IA is a low estimate of the attack rate in this population. 
IA as a complication of COPD is increasingly diagnosed , often post-mortem [45, 46]. Hospital admission rates for 
COPD vary in the UK from 124.7 to 646.5 per 100 000 population annually. If a mean of this (386) is used for the 
population in the European region as defined in this report, then approximately 2 830 000 COPD admissions would 
be expected in Europe annually. Of these, 1.2% develop IA (using longitudinal data for a large Madrid hospital [45], 
or approximately 33 950 patients. Most of these patients currently go undiagnosed and some are admitted to 
medical intensive care units (ICUs) (see below). 
Solid organ transplantation and associated corticosteroid therapy are potent risk factors for the development of IA. 
Rates by transplant type vary and can be estimated individually or collectively. Accurate estimation of the risk in 
Europe is not possible with current data. Using UK data [47] and rebasing it for the main European countries 
indicates that about 30 000 solid organ transplants were done in 2009, but this figure is incomplete, and possibly 
an underestimate, especially with regard to renal transplants. Some countries, such as Belgium or Spain, have high 
organ donation rates, others much lower [48]. A prospective surveillance programme in the USA in 15 transplant 
centres, using the original EORTC/MSG criteria for diagnosis (which have some limitations for solid organ 
transplant recipients) established the overall rate of IA to be 0.75 % [49]. Using this figure, which almost certainly 
underestimates the rates, it is expected that there are ~225 IA patients in this population across Europe.  
More patients with IA are being recognised in medical ICUs. There are estimated to be ~3.3 million admissions to 
ICU beds in Europe, with a seven-fold variation in bed numbers among countries (from 3.3 per 100 000 population 
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in the UK to 24.0 per 100 000 population in Germany) [50] and in number of patients per bed and per year (46–
124 in Austria and Sweden, respectively) [51]. Based on US data it is assumed that around one third are medical 
patients [52]. The proportion of these patients who develop IA is 0.33–5.8 % [53]. For the purposes of estimation 
we have used a 2% rate, indicating that around 22 000 patients develop IA annually in European ICUs. There is 
also the possibility of double counting for some patients in the other risk groups above, which is difficult to fully 
adjust for, because of variable case-mix in different ICUs. On the other hand, some surgical patients also develop 
IA [54]. 
There are other patients at risk who develop IA, including those receiving corticosteroids and other 
immunosuppressive agents. It is not easy to estimate the numbers involved and these patients have therefore 
been omitted here. 
Overall burden and implications of azole 
resistance 
The overall mean burden estimate of all forms of aspergillosis in Europe is approximately 2 400 000 affected 
individuals annually (Table 2). These numbers do not include the estimated 1 870 000 individuals with allergic 
fungal rhinosinusitis which has yet to be demonstrated to respond to antifungal therapy. We estimate that 63 250 
of these patients develop IA, a disease with a high mortality rate requiring urgent therapy. Slightly more than 2.3 
million patients with allergic or chronic aspergillosis could potentially benefit from long-term oral azole therapy. 
Azole resistance is therefore potentially highly problematic for both groups of patients. 
Clinical implications 
Three classes of antifungal agents, the polyenes, the echinocandins, and the triazoles are available for the 
treatment of Aspergillus diseases. The choice of a certain compound is primarily based on the evidence obtained in 
clinical trials. A summary of the antifungal agents and their main use is shown in Table 3. Voriconazole is widely 
agreed to be the agent of first choice for IA. Its superiority as primary treatment for this condition over treatment 
with other classes of antifungals has been demonstrated in a number of clinical trials [55–57]. Only itraconazole 
has been studied for treatment of ABPA and SAFS. 
Table 3. Classes of antifungals 
Class Drug Route of  
administration 
Indication Comment 
Triazole Itraconazole Intravenous/oral Treatment of chronic Aspergillus 
diseases 
 
   Salvage therapy  
 Posaconazole Oral Prophylaxis of invasive fungal diseases  
   Salvage therapy  
 Voriconazole Intravenous/oral Primary therapy of invasive 
aspergillosis (IA) 
 
   Salvage therapy  
Polyene Lipid formulations 
of amphotericin B 
Intravenous Primary therapy of invasive 
aspergillosis (IA) as an alternative 
choice for voriconazole 
High costs 
   Salvage therapy  
Echinocandin Caspofungin Intravenous Salvage therapy Exhibited low efficacy 
as primary therapy of 
IA in phase II trials 
Failure of azole therapy 
Case series consistently show high failure rates of patients with azole-resistant Aspergillus diseases to azole 
therapy. In patients with chronic Aspergillus diseases the failure rate was 89% [4], while in patients with azole-
resistant IA 88% of patients had died within 12 weeks of obtaining a positive culture [10]. The clinical experience 
is supported by preclinical experimental data that show that the probability of azole treatment failure increases 
with increasing minimum inhibitory concentration (MIC) of the isolate [58-65].  
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The majority of azole-resistant A. fumigatus isolates are multi-azole-resistant. In a recent Dutch survey, 82 clinical 
azole-resistant isolates were all resistant to itraconazole (MIC > 2 mg/l), 79% were resistant to voriconazole (MIC 
> 2 mg/l) and 65% to posaconazole (MIC > 0.25 mg/l) (EUCAST breakpoints) [10, 66]. As a consequence, at best 
only a marginal role remains for azoles in the management of azole-resistant Aspergillus diseases. 
Alternative treatment options 
Clinical experience with alternative treatment regimens is limited. The in vitro activity of amphotericin B and 
caspofungin against azole-resistant isolates is similar to that against wild-type isolates, indicating that these agents 
may exhibit similar efficacy to wild-type isolates in vivo [62]. However, for both drug classes clinical evidence that 
these agents are efficacious in azole-resistant disease is lacking. 
Experimental data are available for the combination voriconazole with anidulafungin in azole-resistant invasive 
aspergillosis [67]. These experiments indicate that the drug combination acts synergistically on mice infected with 
a voriconazole-susceptible isolate (MIC 0.25 mg/l). Although the combination showed better survival than 
voriconazole monotherapy in mice infected with a voriconazole-resistant isolate (MIC 4 mg/l), the drug interaction 
was indifferent. This raises concerns regarding the use of a voriconazole-echinocandin combination in isolates with 
high voriconazole MICs (i.e. 8 or 16 mg/l) as efficacy of the combination may then only be due to anidulafungin. 
The efficacy of anidulafungin monotherapy was only 45% in mice infected with the azole-resistant isolate as 
compared to that in mice infected with azole-susceptible isolates. Combinations of either caspofungin or 
micafungin with amphotericin B have been studied and shown not to be antagonistic, but are costly in clinical 
practice. 
Preliminary results of liposomal amphotericin B efficacy in a non-neutropenic model of azole-resistant IA indicate 
that the efficacy of this polyene was not affected by the presence of the TR34/L98H or M220I resistance 
mechanism, compared to a wild-type control isolate (personal communication, P. Verweij). Clearly, more research 
is needed in order to guide decisions for treating patients.  
Specific management problems 
There are two patient groups for whom alternative therapy to azoles is very problematic. The first is treatment of 
azole-resistant central nervous system (CNS) aspergillosis, as voriconazole was found to have a better outcome 
than alternative agents. Case series show a 35% survival in CNS aspergillosis when treated with voriconazole, 
compared to approximately 10% in patients treated with a lipid formulation of amphotericin B, and 1% in patients 
treated with conventional amphotericin [68-70]. In patients with azole-resistant CNS aspergillosis an alternative 
drug with comparable efficacy to voriconazole is not available and successful management of patients is difficult. 
The second group is those with chronic Aspergillus diseases that require long-term antifungal therapy. As the 
azoles are the only class of drugs with activity against Aspergillus spp. that can be administered orally, ambulatory 
treatment would have to rely on intravenous therapy in cases of azole resistance. Increased costs, complications 
associated with intravenous access devices and the need for day admission in specialised healthcare institutions 
may create additional management problems. 
Detection of resistance 
The diagnosis of Aspergillus diseases can be difficult and cultures may remain negative. The detection of azole 
resistance further complicates the diagnosis and may result in delayed initiation of adequate antifungal therapy. In 
culture-positive patients in vitro susceptibility testing can be performed, which takes up to five days to complete. 
Rapid agar-based screening tools are being developed that may give an indication of resistance earlier [71]. In 
culture-negative patients, molecular tools can be used by detection of resistance mutations directly in clinical 
specimens. Although proof of principle has been reported, there are problems regarding the sensitivity of the assay, 
as the resistance hot spot gene is a single copy gene. Nevertheless, in one study resistance mutations were found 
in 55% of respiratory samples obtained from patients with chronic lung diseases [72]. This patient group is clearly 
different from those with IA, which is a rapidly lethal disease if treated inappropriately. As azole resistance may be 
present in azole-naive patients, the use of molecular tools to detect mutations directly on clinical specimens may 
enable rapid detection of resistance. However, there is an increasing list of mutations that are associated with 
azole resistance in A. fumigatus and in an increasing proportion of isolates the resistance mechanism is unknown. 
This limits the use of PCR-techniques and would require the development of new tools, such as sequence-based 
assays. 
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Routes of resistance development 
Resistance has been shown to develop in patients with aspergilloma and cavitary lung disease who have been 
treated with azoles. Pathogenesis involves infection of the patient with an azole-susceptible A. fumigatus isolate 
that becomes resistant due to azole pressure. From patients receiving long-term azole treatment, azole-resistant A. 
fumigatus isolates have indeed been described to contain numerous point mutations including those in codons 54 
and 220 of cyp51A [5-8, 73]. This confirms the general thought that these resistance mechanisms are gained 
under high azole pressure within the patient. Substantial diversity of cyp51A-related resistance mechanisms has 
therefore been found which was shown to be associated specifically with azole therapy [5]. Importantly, spread of 
resistance is highly unlikely in IA, because person-to-person transmission is very uncommon and a patient will 
either respond to treatment (precluding spread of the isolate) or the treatment will fail. In the latter case, the 
(resistant) fungus might survive, but its spread directly to another patient or through the environment seems highly 
unlikely. Patient-to-patient transmission of IA is extremely uncommon, and reports have only been published of two 
clusters: transplantation of a contaminated allograft and a surgical wound infection [74, 75]. 
Another route of resistance development might be through exposure of A. fumigatus to azole compounds in our 
environment. Exposure of saprophytic fungi to azole compounds could take place in agriculture, where such compounds 
are commonly used for plant protection. The fungicides are applied repeatedly over a long period of time and could 
thereby create a persistent pressure of azole compounds on saprophytic fungi. During the saprophytic growth of 
Aspergillus spp. in the environment, the asexual and sexual reproductive modes not observed in patients with acute IA 
may promote the efficient spread of particular mutations well adapted to the selective pressures exerted by azole 
compounds. Furthermore, an environmental route of resistance development would be in line with the finding of primary 
IA due to azole-resistant A. fumigatus in azole-naive patients. Breakthrough aspergillosis in patients on azole prophylaxis 
would also be consistent with an environmental route: patients would inhale both azole-susceptible and azole-resistant 
conidia, but the resistant conidia would have a selective advantage, thus allowing their germination in the lungs and 
subsequent invasive disease. This route of resistance will be further elaborated in the next paragraph. 
Evidence for the environmental route 
The following observations support an environmental route of azole resistance development: 
• Azole resistance observed in azole naïve patients. A recent Dutch culture-based survey in seven 
university medical centres showed that 64% (14/22) of patients with azole-resistant Aspergillus spp. disease 
known to have been exposed to azole were azole naïve at the time the resistant isolate was cultured [10]. As 
patients are exposed to Aspergillus spp. primarily through inhalation of airborne conidia, this observation 
suggests that azole-resistant spores are present in the air. Patients are thus exposed to azole-susceptible and 
azole-resistant spores and either could go on to cause Aspergillus disease in a sensitive host. Treatment with 
azoles could favour the germination of those conidia that harbour a resistance mechanism. 
• A dominant resistance mechanism is found in the Netherlands. In the Netherlands the dominant 
resistance mechanism consists of a substitution at codon 98 (L98H) and a 34-base pair tandem repeat in the 
gene promoter (TR34/L98H). Two surveillance studies have reported this specific resistance mechanism in >90% 
of clinical isolates found to be itraconazole resistant [9, 10]. This contrasts with observations in patients with a 
documented patient route of resistance development, characterised by a wide diversity of mutations in 
consecutive cultures from different colonies recovered from a single specimen. As Aspergillus diseases are not 
contagious, patient-to-patient spread of isolates (and resistance mechanisms) is highly unlikely, the finding of 
a dominant resistance mechanism is not in keeping with the patient route. 
• The presence of two genomic changes (including a tandem repeat).The dominant resistance 
mechanism found in the Netherlands consists of two genetic changes, while isolates that have become 
resistant through patient therapy tend to have a single mutation as underlying resistance mechanism [76]. The 
development of a complex resistance mechanism during azole therapy may be less likely. Furthermore, a 
tandem repeat has been found as resistance mechanism in phytopathogenic fungi that have become resistant 
to azole fungicides. 
• Isolates harbouring the TR34/L98H resistance mechanism are found in the environment. Several 
studies have shown that A. fumigatus isolates from environmental samples may be resistant to medical triazoles. 
This has been found in soil samples obtained from flower beds, compost, leaves and seeds purchased from a 
commercial garden centre [77]. The resistance mechanism found in the majority of isolates cultured from the 
environment is TR34/L98H. Moreover, TR34/L98H isolates of environmental origin have been reported in the 
Netherlands, Denmark, Norway, the UK and Italy [77, 78]. Genetic typing of TR34/L98H isolates of clinical and 
environmental origin using microsatellites showed that TR34/L98H isolates clustered and were less diverse than 
wild-type controls and azole-resistant isolates with point mutations as the underlying resistance mechanism [79]. 
• Triazole fungicides used in agriculture have a similar molecular structure to medical triazoles. 
Molecule alignment studies and docking experiments using a homology model of active site of the Cyp51A 
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enzyme have identified five triazole fungicides that are very similar to the medical triazoles. These fungicides 
include propiconazole, tebuconazole, epoxiconazole, difenoconazole and bromuconazole. Bioinformatic analysis 
showed that the presence of the L98H mutation most hindered the docking of the triazole fungicides with a 
structure similar to the medical triazoles. Furthermore, the findings were consistent with in vitro susceptibility 
testing, which showed that these compounds were active against wild-type A. fumigatus, but inactive against 
TR34/L98H isolates. Furthermore, the five triazole fungicides were authorised for use in the Netherlands 
between 1990 and 1996, which preceded the first culture of TR34/L98H from a clinical specimen in 1998 [80]. 
• Absence of genotypical wild-type isolates related to those with TR34/L98H. In some patients who 
have developed azole resistance during azole therapy, isogenic isolates have been recovered with a wild-type 
phenotype. This indicated that the resistance mechanism developed through the exposure to azoles. However, 
in patients from whom TR34/L98H isolates were recovered, an identical or strongly related isolate with a wild-
type phenotype has never been recovered. In specific patient populations where repeated cultures are 
available, (e.g. patients with cystic fibrosis) there has repeatedly been no relation to previously cultured wild-type 
isolates. This observation supports an exogenous source of TR34/L98H. 
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Use of triazoles and other sterol demethylation 
inhibitor (DMI) fungicides in agriculture 
Since their introduction more than thirty years ago, azoles have played an important role in agriculture and 
horticulture [81]. Because of their excellent systemic broad-spectrum eradicant and protectant properties, azoles 
are for many crops (e.g. cereals and soybean) the most important fungicide group to protect from diseases, 
ensuring yields and preventing fungal contamination of produce, thus ensuring produce quality. 
DMI fungicides represent the largest class of fungicides in agriculture and horticulture, with 26.1% of total 
fungicide sales (USD 8 916 million) globally reported in 2005 [82]. Detailed data on the use of DMI fungicides are 
not available from all countries. Although the absolute amounts used will differ, the compounds and their purposes 
are assumed to be similar throughout the EU. As examples of the use of DMI fungicides in agriculture we chose 
data from the United Kingdom, the Netherlands and Denmark. Figure 1 shows the amounts of individual DMI 
fungicides used for crop protection in these three countries in 2008. 
Figure 1. Use of triazoles in agriculture in the United Kingdom, the Netherlands and Denmark, 2008 
(logarithmic scale) 
 
UK: data were collected by the Pesticide Usage Survey Teams at the Food and Environment Research Agency (FERA) and the 
Scottish Agricultural Science Agency (SASA). Fungicide use by government, industry/forestry and garden/household is not 
included.  
NL. Data were obtained from the Central Bureau of Statistics (Statistics Netherlands). Data on fungicide use by government, 
industry/forestry and garden/household is included.  
DK: Data collected by the Danish Environmental Protection Agency (Miljøstyrelsen) 4/2009. 
Most of the listed DMI fungicides are triazoles. The exceptions are the imidazoles (imazalil, prochloraz and 
triflumizole), the pyridine pyrifenox and the piperazine triforine. Triazoles (e.g. prothioconazole, epoxiconazole, 
tebuconazole, cyproconazole, metconazole, propiconazole, difenoconazole and flusilazole) and the imidazole 
prochloraz are most commonly used on arable crops (e.g. wheat, barley, oilseed rape and beans), controlling 
septoria leaf blotch, rhynchosporium, Fusarium, rusts and mildews. These are therefore used over the largest areas 
and in the highest amounts. Other triazoles (e.g. triadimenol, fluquinconazole, triticonazole, flutriafol, bitertanol) 
and prochloraz are used as seed treatments for cereal crops to control Fusarium seedling blight on wheat, and 
loose smut and leaf stripe on barley. Prochloraz is also used to sterilise bulbs (e.g. narcissus, tulip and hyacinth), 
whereas other triazoles such as myclobutanil, penconazole and fenbuconazole are used to control diseases of 
outdoor bulb/flower crops, vegetables, soft fruit, ornamental crops and orchards (e.g. Alternaria fruit rot, Botrytis 
crown rot, apple scab, downy mildew and mildew). Table 4 shows in more detail how different DMI containing 
products are used in some key crops in the UK.   
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Table 4. Use of triazole fungicides in the production of selected crops/commodities in the United 
Kingdom 
Crop Yeara Production 
area (ha) 
Key triazole fungicide 
productsb 
Area  
treated 
(ha)c 
Amount 
used 
(kg) 
Average  
spray  
numberd 
Average  
dose  
ratee 
Beans 2008 118 462 Tebuconazole 65 691  10 222  1.32 0.62 
   Cyproconazole/chlorothalonil 24 899  14 938  1.19  0.72 
Carrots 2007 15 380 Tebuconazole 11 131 2 328 1.56 0.84 
Wheat 2008 2 068 104 Epoxiconazole 1 242 366  75 598  1.46  0.49 
   Prothioconazole/tebuconazole 571 313  89 840  1.57 0.54 
Dessert apples 2008 5 577 Myclobutanil 22 356 1 309 4.70 0.64 
   Penconazole 11 987 386 3.30 0.65 
Field roses 2009 324 Myclobutanil 446 20 2.47 volumetric 
Herbaceous 
plants 
2009 910 Prochloraz/propiconazole 163 39 4.00 0.39 
Hops 2008 1 071 Myclobutanil 4 139 162 4.86 volumetric 
Oilseed rape 2008 597 706 Flusilazole/carbendazim 286 508  44 283  1.26  0.52 
   Prothioconazole 225 120  22 877  1.24 0.58 
   Metconazole 180 784  7 442  1.15 0.57 
Outdoor bulbs 2009 4 875 Tebuconazole 6 311 966 1.65 0.61 
Strawberries 2006 4 480 Myclobutanil 8 084 634 2.35 0.85 
Vines 2006 856 Myclobutanil 1 577 80 2.62 1.02 
a Year when crops were surveyed by the Food and Environment Research 
Agency (FERA) and the Scottish Agricultural Science Agency (SASA). Wheat 
and beans includes winter and spring grown varieties. 
b Triazoles were applied as solo or in mixtures with other 
sterol demethylation inhibitors or fungicides with different 
modes of action. 
c Area treated is the total number of hectares sprayed. 
d Average spray number is the average number of 
applications of the product on the area treated. 
e Average dose rate is defined as the average proportion of full label rate.  
It is clear that the highest amounts of DMI fungicides are used to control diseases in arable crops, grown over 
large areas and sprayed on average three times in winter (e.g. wheat). The highest selection pressure is on 
diseases of soft fruit, herbaceous plants, hops and fruit trees where some products are applied up to six times 
during the season as part of the fungicide programme. Due to the selection pressure created by DMI fungicides, 
resistance or decreased sensitivity has been reported for key crop/commodity pathogens such as Mycosphaerella 
graminicola (wheat), Rhynchosporium secalis (barley), Botrytis cinerea (strawberry), Pyrenopeziza brassicae 
(oilseed rape), Venturia inaequalis (apple) and Monilinia fructicola (stone fruit). In order to control the rate of 
resistance development, the Fungicide Resistance Action Committee (FRAC), has devised guidelines for the use of 
DMI fungicides based on the rotational use of fungicides with different modes of action, limiting the number of 
applications of particular products and recommending use of products at label rates [83]. 
A recent EU Regulation (1107/2009) ‘concerning the placing of plant protection products on the market’ and a 
Directive (2009/128/EC) adopted at the same time on ‘establishing a framework for Community action to achieve 
the sustainable use of pesticides’ could have implications on the future registration and use of pesticides, including 
DMI fungicides, in the EU. 
Non-agricultural use of triazole fungicides 
The triazoles difenoconazole, tebuconazole and propiconazole are used for the control of key diseases on lawns 
(Fusarium patch, anthracnose and dollar spot) and ornamentals (mildew and rusts) by professionals (greens and 
golf courses) and amateurs (gardening). Tebuconazole and propiconazole complement each other with regard to 
efficacy against wood decaying fungi (e.g. Gloephyllum trabeum and Poria spp.). Together with copper carbonate, 
these fungicides/biocides are the main components of copper organic wood preservatives used in industry to 
pressure treat timbers to achieve long-lasting preventive protection of fencing, cladding, plywood, roofing and 
garden decking. Copper-triazole-based preservatives are widely marketed under the Wolmanized® brand in North 
America and the Tanalith® brand across Europe. Wood preservatives containing propiconazole and tebuconazole 
are also available for domestic curative use. Propiconazole for example is registered for use in adhesives, paints, 
leather, paper and textiles [84] and is available in the UK as the active ingredient in an antifouling agent, biocidal 
paints and surface biocides. 
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What happens if we do nothing? 
If left unchecked, azole resistance could continue to spread in the environment, especially given the global market 
in produce. The molecular epidemiology of TR34/L98H indicates that the resistance mechanism developed locally 
and isolates harbouring this trait subsequently migrated across the borders of European countries [79]. Isolates 
with the TR34/L98H genetic alteration have also been recovered from Asia (China and India), but it remains unclear 
whether these are genetically similar to the European isolates. 
Another risk is the development of novel resistance mechanisms in the environment as the exposure to azole 
compounds continues. Such a scenario was recently reported in the Netherlands where a new resistance 
mechanism, consisting of a 46-base pair tandem repeat and two cyp51A substitutions (TR46/Y121F/T289A), has 
emerged. Within one year, A. fumigatus isolates harbouring TR46/Y121F/T289A were recovered from 15 unrelated 
patients in six different Dutch hospitals. The characteristics of this resistance mechanism resembled that observed 
for TR34/L98H: a complex resistance mechanism, recovery from azole-naive patients, genotypic clustering apart 
from TR34/L98H and wild-type isolates, and culture of TR46/Y121F/T289A from the environment. It is anticipated 
that TR46/Y121F/T289A will migrate in addition to TR34/L98H, thus accelerating the prevalence of azole resistance 
[85]. 
Given the high frequencies of allergies and asthma, the aging population, the attendant increase in cancers and 
their treatment and the expanding indications for transplantation, the numbers of patients at risk of developing 
aspergillosis looks set to rise relentlessly. The burden of pulmonary disorders is also high and likely to increase. 
Under these circumstances, acquisition of an azole-resistant strain of Aspergillus spp. will likely go unnoticed until 
the patient fails initial treatment, typically with a triazole antifungal. Hence, the burden of disease may increase 
further for the individual patient who will require other treatments for longer periods, thus increasing medical costs 
that are already being stretched even in the better-performing economies. It is also unlikely that new medical 
antifungals will become available in the near future. Consequently, we will have to make do with the ones we 
already have. Widespread azole resistance will inevitably mean the loss of one of the three classes of antifungals 
currently employed to treat aspergillosis. Moreover, none of the echinocandins has been licensed as first-line 
treatment of the disease which, if azole resistance becomes widespread, will only leave amphotericin B, albeit in 
different formulations, for patient treatment. Even if echinocandins prove effective, both they and amphotericin B 
formulations must be administered intravenously several times a week, which usually requires day admission at a 
healthcare facility. The future will look bleak indeed for the patient and society as a whole should the azole 
resistance become widespread.  
Although the threat is evident, at the moment we can only provide an educated guess as to the extent of the 
danger involved. Hard facts are required which must be obtained under the right circumstances, as in the 
Netherlands which has the highest rate of environmental azole-resistant Aspergillus spp. It is important to 
determine the balance between the costs and benefits of azole use in human health on the one hand and non-
medical purposes on the other hand. Specifically, the source of azole resistance must be confirmed and the effect 
of reducing azole fungicide use on resistance must be investigated to ascertain whether it will have a measurable 
effect. It has been shown that azole-resistant A. fumigatus isolates that harbour a cyp51A-mediated resistance 
mechanism have a similar fitness or virulence to wild-type isolates [86]. Both in vitro and experimental research 
indicates that there is no loss of virulence in these azole-resistant isolates. This has also been shown for TR34/L98H. 
It is clear that TR34/L98H could not have survived in our environment in competition with wild-type isolates if its 
fitness had been reduced. It is therefore important to investigate what the impact will be if exposure to certain 
azole fungicides is removed. 
This will require funding and concerted efforts being made by all interested parties to share information and 
expertise. 
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Recommendations 
• Improve epidemiological surveillance through: 
− Routine triazole susceptibility testing for clinical isolates (if antifungal treatment is indicated); 
− Increased and continuous surveillance of triazole resistance in A. fumigatus in each EU Member State;  
− Strengthen mycology function at ECDC to monitor disease frequency and triazole resistance, 
facilitate Member State adoption of recommendations and impact of any public health interventions. 
• Develop molecular methods to detect triazole resistance in culture-negative specimens and implement them 
in laboratory practice. 
• Investigate the environmental origin through environmental and laboratory studies, including: 
− Field studies with different triazoles which are putative resistance generators with quantitative and 
sensitive means of detecting triazole resistance in the environment; 
− Extensive and continued environmental studies; 
− Non-agricultural studies (triazoles are also used extensively by industry, application professionals and 
amateurs for disease control of lawns/ornamentals and preservation of materials such as wood, 
coating/paints and plasters); 
− Studies on the reversal of rising resistance rates by restricting certain triazole applications will help to 
identify appropriate public health measures. 
Summary of evidence 
The molecular basis of the development of antifungal drug resistance is not well understood and needs to be 
investigated further to assess the impact and development of this phenomenon. Over the last few years, evidence 
has been accumulating to indicate an environmental route of resistance development which could have serious 
implications for the management of infected patients. Both the health and economic consequences of such a 
development would be considerable, though difficult to quantify as the available data are incomplete for many 
countries. Importantly, aspergillosis is an environmentally acquired infection. Evidence indicates that azole 
resistance in Aspergillus fumigatus is emerging, not only in the Netherlands but also in other European countries 
and possibly globally, and that the development of resistance may in part be environmentally driven. Evidence that 
supports this environmental route of resistance development includes: 
• the presence of azole-resistant Aspergillus disease in azole-naive patients; 
• the dominance of a single and stable resistance mechanism (TR34/L98H); 
• the presence of a tandem repeat in the promoter of the target gene cyp51A, which is a genomic change not 
found in any of the A. fumigatus isolates that have become resistant through patient therapy, but present in 
azole-resistant phytopathogenic moulds; 
• the recovery of A. fumigatus isolates from the environment in Europe which genetically cluster to patient A. 
fumigatus TR34/L98H isolates and are distinct from susceptible (wild-type) A. fumigatus isolates; 
• the medical azole-resistant A. fumigatus isolates are cross-resistant to five triazole fungicides (propiconazole, 
tebuconazole, epoxiconazole, difenoconazole, and bromucazole) that were introduced for agriculture use 
between 1990 and 1996, just preceding the first culture of TR34/L98H from a clinical specimen in 1998, and 
• molecule alignment and docking of these five triazole fungicides into the active site of the Cyp51A enzyme 
are identical to that of the medical azoles.  
Similarly, there is also evidence that: 
• the fitness of the TR34/L98H A. fumigatus isolates is not affected by the mutation; 
• TR34/L98H associated resistance is generally correlated with multi- or pan-azole resistance; 
• patients infected with an azole-resistant A. fumigatus isolate are less likely to respond to therapy resulting 
in an unacceptably high mortality rate approaching 90%;  
• the five triazole fungicides (propiconazole, tebuconazole, epoxiconazole, difenoconazole, and bromucazole) 
are extensively used in the environment for crop protection (e.g. cereals, fruit, vegetables, flowers and 
ornamentals), control of lawn diseases and preservation of materials all over the EU; 
• in addition to the TR34/L98H, comparable resistant mechanisms evolve with other resistant phenotypes due 
to azole fungicide exposure, thereby extending the problem of the emerging of A. fumigatus resistance. 
 
In spite of the data supporting an environmental origin of the multi-azole resistance in A. fumigatus due to the 
TR34/L98H mutation, several uncertainties still exist. Estimates of the prevalence and spread of multi-azole 
resistance in A. fumigatus due to the TR34/L98H mutation are currently based on a small number of studies from a 
few European countries. Existing data show a strong variation in the frequency and composition of the mutations 
associated with azole resistance between the centres within and between European countries. It is currently 
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unclear to what extent these differences are driven by host or environmental factors. Although as shown there is 
accumulating evidence for an environmental origin of multi-azole resistance in A. fumigatus, this link still needs to 
be proven. Association of certain azole fungicides with the observed resistance mechanism appears likely, yet it is 
unclear which exposures represent the main drivers for resistance development in Aspergillus spp. 
In order to understand the epidemiology and origin of azole-resistant A. fumigatus in Europe and to encounter and 
battle this very significant problem, it is essential: 
• to obtain good and reliable data from the EU concerning A. fumigatus resistance in the patient population 
and the environment and 
• to further identify the cause or the sources of the development of azole resistance in both the clinical 
setting and the environment. 
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